Rush Medical Center Home Page Information for healthcare Professionals Rush University
FIND A DOCTOR
PATIENT & VISTOR SERVICES
HEALTH INFORMATION
CLINICAL SERVICES
EVENTS & CLASSES
RUSH NEWS ROOM
CLINICAL TRIALS
RESEARCH AT RUSH
NURSING AT RUSH
WORK AT RUSH
GIVING TO RUSH

Bookmark This Page
Clinical Services at Rush Gary L. Schaer, MD
Gary L. Schaer, MD  
Gary L. Schaer, MD 

Gary L. Schaer, MD, is professor of medicine and director, cardiology research & strategic development at at Rush University Medical Center in Chicago. He is a graduate of Yale University School of Medicine and was a medical resident at the New York Hospital-Cornell Medical Center. He completed a cardiology fellowship at Georgetown University and a critical care medicine fellowship at the National Institutes of Health.

Before joining the Section of Cardiology at Rush University Medical Center in July 1989, he was an assistant professor of medicine and director of the Cardiovascular Research Laboratory at Georgetown University.



Schaer's research interests focus on evaluating new interventional and drug therapies for patients with coronary and peripheral arterial disease. Schaer's RIHVR (Rush Interventional Heart and Vascular Research) Group is currently enrolling patients in drug and device trials, including several important studies employing growth factors or stem cells to stimulate heart angiogenesis (the growth of new blood vessels), and stem cells to improve heart contractile function after a heart attack. Schaer also supervises an experimental catheterization laboratory in the Cohn Research Building, where new approaches are developed and tested.
 
Schaer has authored or coauthored more than 200 original articles, book chapters, editorials and abstracts. He is a sought-after lecturer on topics in interventional heart and vascular disease in Chicago, the United States and internationally.

Schaer's Current Clinical Trials

Marvel Stem Cell Treatment Study: Study of a stem cell treatment using an investigational injection catheter in post MI congestive heart failure patients.

Acord Trial: Treatment Study for No-Option Heart Patients with Coronary Artery Disease: Injections into the heart with a human recombinant (protein) fibroblast growth factor (FGF- investigational compound) compared to placebo. The goal is to stimulate the growth of new blood vessels around blocked coronary arteries.

Osiris PROCHYMAL Stem Cell Treatment Study:
Study of PROCHYMAL (cultured adult human mesenchymal stem cells) administration to preserve or improve cardiac function following heart attack







Promotional Information

Cardiology
Cardiology Faculty and Staff
Gary L. Schaer, MD


Related Topics
   
Find a Doctor | Patient & Visitor Services | Health Information
Clinical Services | Events & Classes | Rush News Room | Clinical Trials
Research At Rush
Disclaimer | Privacy Statement | Site Map

© Rush University Medical Center, Chicago, Illinois